Navigation Links
Bayer and Onyx Announce Nexavar Data Presentations at 35th European Society for Medical Oncology Congress
Date:10/7/2010

MILAN, Oct. 7 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that more than 20 studies evaluating the use of Nexavar® (sorafenib) tablets will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, October 8-12, 2010 in Milan, Italy.

"It's been almost five years since the approval of Nexavar in its first indication, advanced kidney cancer, and since that time the continuum of development in other areas has produced clinically significant findings, leading to a second approval in unresectable liver cancer," said Dimitris Voliotis, Vice President, Global Clinical Development Oncology, Bayer HealthCare. "Our dedication to the development of Nexavar is demonstrated by the array of data being presented at this year's ESMO Congress as well as the ongoing clinical trial program evaluating Nexavar in a variety of treatment settings and patient types."

Nexavar's Differentiated Mechanism

Nexavar, an oral anti-cancer therapy, is currently approved in more than 95 countries for liver cancer where it remains the only approved systemic agent proven to extend survival and in more than 95 countries for the treatment of patients with advanced kidney cancer.  Nexavar inhibits processes involved in both the tumor cell and tumor vasculature.  In preclinical studies, Nexavar has been shown to inhibit members of two classes of kinases thought to be involved in both cell proliferation (growth) and angiogenesis (blood supply) – two important processes that enable cancer growth.  These kinases included Raf kinase, VEGFR-1, VEGFR-2, VEGFR-3, PDGFRB, KIT, FLT-3 and RET.  

Nexavar is also being evaluated by the companies, international study groups, government agencies and individual investigators.

Important Safety Considerations For Patien
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... KANSAS CITY, Kan. , Sept. 18, 2014 ... ), a pet therapeutics company focused on licensing, ... animals, today announced the full exercise of the ... common stock in connection with the company,s previously ... stock.  All of the shares are being offered ...
(Date:9/18/2014)... 2014  LABSCO, the leading specialty sales ... to hospitals, physician office laboratories and alternate ... agreement with Sysmex America.  This agreement is ... the Sysmex XS-1000 i ™, Sysmex pocH-100 ... Automated Hematology Analyzers. The agreement ...
(Date:9/18/2014)...   MacPractice,s MacPractice MD MU version 5.0 ... which designates that the software is capable of supporting ... 2 Meaningful Use measures required to qualify for funding ... MD MU version 5.0 was certified on June 6, ... the National Coordinator-Authorized Certification Body (ONC-ACB) and is compliant ...
Breaking Medicine Technology:Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2LABSCO Renews Sysmex Distributorship Agreement 2LABSCO Renews Sysmex Distributorship Agreement 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... Nov. 16, 2010 eMix , a new business venture ... of its cloud-based image sharing technology for studies and ... expansion into the European marketplace, starting in Germany, Austria and Switzerland. ... features are: Automated report delivery – Enables a ...
... 2010 Berger & Montague, P.C. and ... for Lead Plaintiff and the Class in ... announced the following:IN THE UNITED STATES DISTRICT ... HEMISPHERX:BIOPHARMA, INC. LITIGATION:CIVIL ACTION NO.  09-CV-5262-PSD:SUMMARY NOTICE ...
Cached Medicine Technology:At RSNA, eMix to Exhibit EMR Delivery, Other New Features 2Summary Notice of Proposed Settlement, Settlement Fairness Hearing, and Motion for Award of Attorneys' Fees and Reimbursement of Litigation Expenses 2Summary Notice of Proposed Settlement, Settlement Fairness Hearing, and Motion for Award of Attorneys' Fees and Reimbursement of Litigation Expenses 3
(Date:9/18/2014)... When Mary Ann Thompson and Mathieu Nikel decided it ... Bali, Indonesia with their son, Isaac, said there was only one ... Mercy College in 2001 when Thompson was an undergraduate student and ... student at the time, was French and so she asked him. ... the United States when she was 7 years old. Nikel ...
(Date:9/18/2014)... 2014 Dr. David A. F. Ellis ... American Academy of Facial Plastic and Reconstructive Surgery and ... Division of Facial Plastic Surgery. He is recognized ... surgery. , Dr. Ellis will be presenting on ... presenting on injection techniques and various treatments for complications ...
(Date:9/18/2014)... News) -- Rising temperatures in the Atlantic Ocean may ... waters that are becoming warmer, an expansion that could ... A study of 40 species along the reefs ... the invasive and poisonous lionfish, according to researchers from ... University of North Carolina-Wilmington, who published their findings in ...
(Date:9/18/2014)... September 18, 2014 It’s been just a ... newest, patent pending bunion splint to website visitors, but already ... wrote: "I was absolutely delighted. It is perfect and I ... am wearing them. THANK YOU FOR LISTENING!!!" Another user ... saying, "The hole used to slip to the end of ...
(Date:9/18/2014)... Amy Norton HealthDay Reporter ... single dose of a common antidepressant can quickly alter the ... The findings, reported online Sept. 18 in ... brain,s response to widely prescribed antidepressants. Experts said the hope ... depression are likely to benefit from a drug -- and ...
Breaking Medicine News(10 mins):Health News:For The First Time in Over a Decade Mercy College Alumni Marry at College 2Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Rising Atlantic Ocean Temperatures Could Pose Threat to Reefs 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 2Health News:Feedback for the New Bunion Bootie Design Feedback is Already Pouring In, and Bunion Sufferers Love It 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3
... in sub-Saharan Africa do not necessarily lead to a higher ... Friday. ,Contradicting a "common belief" of such ... for Refugees (UNHCR) said that out of 12 refugee camps ... rate than surrounding host communities. ,The study, led ...
... 105-year-old exile who was detained for 30 years in his native ... citizen at a ceremony in Miami. ,Now, he ... ,And the former fisherman is convinced he will outlive the ... ,"He's far less healthy than I am, he can hardly ...
... lovers, otherwise allergic, beware. Cuddling your pet could prove ... found that a protein secreted from the cats skin could ... in people who have no specific allergy to the animals. ... suffer from allergy of one kind or another. ...
... of The American Journal of Medicine, researchers from the ... people 45 to 64 years of age who added ... cardiovascular disease (CVD) and reduce their death rate. ... at least 5 fruits and vegetables daily, exercising at ...
... - a molecule originally considered only a lowly messenger for ... where they are in the body and what they ... Medicine have discovered. ,The finding implies that ancient ... the human genome - a cell's genetic blueprint. It also ...
... autoimmune disease that mainly affects women in their reproductive ... improving quality of life. ,For men with ... However, no studies have been conducted to date on ... male SLE patients. In addition, the study identified intravenous ...
Cached Medicine News:Health News:No Clear Link Between Conflict, Rape and HIV: UN Study 2Health News:The American Dream Comes True for 105-year-old Cuban 2Health News:Allergic Individuals Should Keep Away from Cats, Say UK Scientists 2Health News:Allergic Individuals Should Keep Away from Cats, Say UK Scientists 3Health News:Healthy Lifestyle can Reduce Cardiovascular Risk 2Health News:RNA Play a Vital Role in Gene Activity 2Health News:RNA Play a Vital Role in Gene Activity 3Health News:RNA Play a Vital Role in Gene Activity 4Health News:Infertility is Seen in Men With SLE 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: